SEC Comment Letter 0000000000-26-003380 to Benitec Biopharma Inc. (BNTC)

Benitec Biopharma Inc.
Date: April 3, 2026 · CIK: 0001808898 · Accession: 0000000000-26-003380

View on Edgar

AI Filing Summary & Sentiment

Sentiment

Urgency

Document Type

Confidence

SEC Posture

Company Posture

Summary

Reasoning

File numbers found in text: 001-39267

Date

April 3, 2026

Author

Megan Boston

Form

UPLOAD

Company

Benitec Biopharma Inc.

Letter

April 3, 2026 Megan Boston Chief Financial Officer Benitec Biopharma Inc. 3940 Trust Way Hayward, California 94545 Re:Benitec Biopharma Inc. Form 10-K for Fiscal Year Ended June 30, 2025 File No. 001-39267 Dear Megan Boston: We have completed our review of your filings. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Sincerely, Division of Corporation Finance Office of Life Sciences

Show Raw Text

April 3, 2026
Megan Boston
Chief Financial Officer
Benitec Biopharma Inc.
3940 Trust Way
Hayward, California 94545
Re:Benitec Biopharma Inc.
Form 10-K for Fiscal Year Ended June 30, 2025
File No. 001-39267
Dear Megan Boston:
            We have completed our review of your filings. We remind you that the company and its
management are responsible for the accuracy and adequacy of their disclosures, notwithstanding
any review, comments, action or absence of action by the staff.
Sincerely,
Division of Corporation Finance
Office of Life Sciences

SecProbe.io